HLA-B27 transgenic mice are susceptible to collagen-induced arthritis: type II collagen as a potential target in human disease.
HLA-B27 is highly linked with a group of human diseases called spondyloarthropathies (SpA). Many of these disorders begin after an infection with an enterobacteria. The symptoms seen in patients with spondyloarthropathies are inflammatory pain in the spine and asymmetrical arthritis of lower limbs. Additional symptoms related to SpA include inflammation in the eyes, bowel, and skin. The autoantigen(s) in SpA are not known. Proteins such as collagen and proteoglycans have been thought to be potent autoantigens in arthritidis including B27-associated human diseases. Type II collagen is a common denominator among eyes and joints, affected tissues in B27-linked diseases. Moreover, a few reports indicated CII specific T cells and antibodies in patients with spondyloarthropathies. We and others have previously described development of spontaneous arthritis and nail disease in HLA-B27 transgenic animals. To determine whether CII may be a target antigen in the B27-linked diseases, B27 + m beta 2 m% (HLA-B27) transgenic mice lacking mouse beta 2m with and without human beta 2m) mice were immunized with type II collagen inside the barrier facility. Male HLA-B27 transgenic mice developed collagen-induced arthritis compared to transgene negative littermates or female counterparts. There was no difference in the incidence of arthritis in HLA-B27 transgenic mice with and without human beta 2m. Our data suggest that beta 2m free heavy chain of HLA-B27 may present soluble antigens such as type II collagen to trigger specific T cells contributing in the development of arthritis. Our data also suggest that CII may be a potential target antigen in the cartilage during the disease process.
Lee
S
S
Department of Immunology, Mayo Clinic & Medical School, Rochester, MN 55905, USA.
Khare
S D
SD
Griffiths
M M
MM
Luthra
H S
HS
David
C S
CS
D000818:Animals; D000906:Antibodies / Q000097:blood; D000918:Antibody Specificity; D001168:Arthritis / Q000097:blood / Q000209:etiology* / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D003094:Collagen / Q000008:administration & dosage / Q000276:immunology*; D004198:Disease Susceptibility; D005260:Female; D015796:HLA-B27 Antigen / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007114:Immunization; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009260:Nail Diseases / Q000209:etiology / Q000276:immunology; D012737:Sex Factors; D013047:Specific Pathogen-Free Organisms; D001613:beta 2-Microglobulin / Q000172:deficiency / Q000235:genetics
D000906:Antibodies; D001324:Autoantigens; D015796:HLA-B27 Antigen; D001613:beta 2-Microglobulin; D003094:Collagen